Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Breast Neoplasms 16Brain Neoplasms 4Ovarian Neoplasms 3Neoplasm Metastasis 3Endometrial Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Neoplasms by Site 2Neoplasms 2Glioma 2Glioblastoma 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Diseases 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Solid Tumor, Adult 1Sarcoma, Kaposi 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Rectal Neoplasms 1Prostatic Neoplasms 1Osteosarcoma 1Neurofibromatosis 1 1Neuroblastoma 1Multiple Myeloma 1Medulloblastoma 1Lung Neoplasms 1Liposarcoma 1

Interventions

Docetaxel 3pazopanib 2Trabectedin 2Doxorubicin 2toripalimab 1temsirolimus 1sapanisertib 1nilotinib 1liposomal doxorubicin 1lenvatinib 1lentiviral minigene vaccine of COVID-19 coronavirus 1eribulin 1cemiplimab 1avelumab 1abemaciclib 1Sunitinib 1Specimen Handling 1Radiotherapy 1Nivolumab 1Methotrexate 1Imatinib Mesylate 1Ifosfamide 1HhAntag691 1Gemcitabine 1Epirubicin 1Dacarbazine 1Cisplatin 1Biopsy 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Leiomyosarcoma × abemaciclib × Clear all
NCT06498648 2026-05-13

Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma

National Cancer Institute (NCI)

Phase 1/2 Recruiting
74 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡